Arrow Fat Left Icon Arrow Fat Right Icon Arrow Right Icon Cart Icon Close Circle Icon Expand Arrows Icon Facebook Icon Instagram Icon Hamburger Icon Information Icon Down Arrow Icon Mail Icon Mini Cart Icon Person Icon Ruler Icon Search Icon Shirt Icon Triangle Icon Bag Icon Play Video

Completed Research Studies

  • Phase III open – label period followed by a randomized double – blind, placebo – controlled study of the analgesic efficacy and safety of extended release hydrocodone/acetaminophen (Vicodin ® CR) compared to placebo in subjects with chronic low back pain.
  • Phase II, randomized , double – blind, placebo – controlled, proof of concept, efficacy and safety study of FK 555 and naproxen in treating the signs and symptoms of osteoarthritis of the knee.
  • A randomized, double – blind, multicenter, parallel – study evaluating the efficacy and safety of a combination of Ramipril plus Hydrochlorothiazide versus the component monotherapies in subjects with essential hypertension.
  • A six week double blind, randomized, multicenter comparison study of the analgesic effectiveness of Celecoxib 200 mg compared to Tramadol Hydrochoride 50 mg QID in subjects with chronic low back pain.
  • A long – term, open – label extension study to investigate the long term safety of SYR110322 (SYR-322) in subjects with type 2 diabetes.
  • A multicenter, randomized, double blind, placebo controlled study to determine the efficacy and safety of the combination of SYR-322 and Poglitazone HC1 (ACTOS ®) in subjects with type 2 diabetes.
  • A multicenter, randomized, double blind, placebo controlled study of the safety and efficacy of CS-917 as monotherapy for type 2 diabetes.
  • A multicenter, randomized, double blind placebo controlled, parallel group study of oral MOA-728 for the treatment of opioid induced bowel dysfunction in subjects with chronic non malignant pain.
  • Phase II, double blind randomized, placebo controlled parallel group, multicenter study to evaluate daily treatment with SYR-472 in subjects with diabetes.
  • Phase IIIB, double blind, randomized study to determine the efficacy and safety of piolitazone HCL and Metformine HCL monotherapy to Metformin HCL monotherapy in the treatment of subjects with type II diabetes.
  • Phase IV 12 week, multicenter, double blind, and randomized placebo controlled efficacy and safety study in adult patients with IBS with constipation.
  • Phase III, multi center, randomized, double blind, controlled study of the long term analgesic efficacy and safety of Tanezumab alone or in combination with non steroidal anti inflammatory drugs (NSAIDS) versus NSAIDS alone in patients with osteoarthritis of the Knee or Hip.
  • A multicenter, randomized, double blind study to evaluate the efficacy and safety of alogliptin compared to glipizide in elderly subjects with type 2 diabetes.
  • A phase IV, multicenter, open label, observational study assessing the impact of exposure to Thrombin-JMI (Thrombin, topical U.S.P. [Bovine Origin]) on coagulation parameters.
  • A randomized, double blind, parallel group study evaluating the efficacy and safety of coadministration of triple combination therapy of Olmesartan Medoxomil, Amlodipine Besylate and a Hydrochlorothiazide in subjects with hypertension.
  • Randomized, double blind, placebo controlled, multi center study of a single injection cross linked Sodium Hyaluronate to provide symptomatic relief of osteoarthritis of the knee.
  • A multicenter, randomized, double blind study to evaluate the efficacy and safety of Alogliptin compared to Glipizide in elderly subjects with type 2 diabetes.
  • A randomized, double blind, parallel group study evaluating the efficacy and safety of co-administration of a triple combination therapy of Olmesartan Medomoxil, Amlodipine Besylate and Hydrochlothiazide in subjects with hypertension.
  • Phase III randomized, double blind, placebo and Oxycodone controlled multicenter study of the efficacy and safety of Tanezumab in patients with osteoarthritis of the knee of hip.
  • Phase Ib, proof of concept study to evaluate the co-administration of TT223 given daily and LY2428757 given once weekly for four weeks in patients with type 2 Diabetes Mellitus.
  • A multi center, randomized, active controlled study to investigate the efficacy and safety of intravenous Ferric Carboxymaltose (FCM) in patients with Iron Deficiency Anemia (IDA).
  • A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study to evaluate the efficacy and safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for patients (12-75 years of age) with eosinophilic Asthma.
  • A multi-center, primary care-based, open-label, study to assess the success of converting opioid experienced patients, with chronic, moderate to severe pain, to EMBEDA using a standardized conversion guide, and to identify behaviors related to prescription opioid abuse, misuse and diversion.
  • Phase 3 - An Open-Label Extension Study to evaluate the long-term safety and efficacy of Reslizumab (3.0mg/kg) as Treatment for patients with Eosinophilic Asthma who completed a prior Cephalon-Sponsored study in Eosinophilic Asthma.
  • Protocol Number and Title: 31-11-283 A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 months with Aripiprazole IM Depot Compared with 6 month Retrospective treatment with Oral Antipsychotics in a Naturalistic Community Setting in the Unites States.
  • Protocol Number: CNDO 201-003 A Phase II Study to evaluate the efficacy and safety of 12 weeks of treatment with oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as compared to placebo, followed by a 12 weeks open-label treatment period in patient with moderately to severely active Crohn's Diseases.
  • Protocol Number and Title: Re: Ferrer, P-110880-01, A phase III 3 arms, multicenter, randomized, investigator blind study to assess the efficacy and safety of ozenoxacin 1% cream applied twice daily for 5 days versus placebo in the treatment of patients with impetigo.
  • Protocol Number and Title: B1481015. A Phase 2B double-blinded, randomized, placebo controlled, parallel group, dose-ranging study to assess the efficacy, safety and tolerability of PF-04950615 following monthly and twice monthly subcutaneous dosing for six months in hypercholesterolemic subjects on Statin.
  • Dr. Reddy’s Laboratories Ltd., Protocol Number DRL-USG01-L/2012, Protocol Title: A Randomized, Double-blind, Double dummy, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Clinical Equivalence of Lubiprostone 24 mcg Capsules (Dr. Reddy’s Laboratories Ltd.) With AMITIZA® (Lubiprostone) 24 mcg Capsules (Sucampo Pharmaceuticals, Inc.) in the Treatment of Chronic Idiopathic Constipation.
  • A0081279: A randomized double blind placebo controlled parallel group study of efficacy and safety of pregabalin (BID) in subjects with post-traumatic peripheral neuropathic pain.
  • Amarin AMR-01-01-0019: A Multi-Center, Prospective, Randomized, Double- Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial)
  • Gloria-AF: Global Registry on Long-Term Oral Anti-thrombotic treatment in Patients with Atrial Fibrillation.
  • RFIB3053: A study to assess repeat treatment efficacy and safety of Rifaximin 550mg TID in subjects with irritable bowel syndrome with diarrhea( IBS-D).
  • A randomized, placebo-controlled, Phase IIb Dose-finding study of CYT003-QbG10, a TLR9-Agonist, in patient with Moderate to Severe allergic asthma not sufficiently controlled on Current standard therapy. (GINA steps 3+4)
  • MB102073: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately controlled hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB).
  • MB102-077 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Controlled Hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication.
  • AIR2010-001-1204-01 A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Determine the Therapeutic Equivalence of a Generic Diclofenac Sodium Topical Gel 1% and Voltaren® Gel in Subjects with Osteoarthritis of the Knee.
  • 1275.9 A phase III, randomised, double-blind, parallel group study to evaluate efficacy and safety of empagliflozin 10 mg and empagliflozin 25 mg as add on therapy to linagliptin 5 mg compared with linagliptin 5 mg alone, administered orally once daily for 24 weeks, in patients with type 2 diabetes mellitus and insufficient glycaemic control after 16 weeks treatment with linagliptin 5 mg once daily on metformin background therapy.
  • Cardiovascular Inflammation Reduction Trial (CIRT):A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome.
  • NN9068-3851: The efficacy of insulin degludee/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and OAD therapy.
  • DAS181-2-04: Randomized, double-blind, placebo-controlled Phase 2B study on safety and therapeutic efficacy of DAS181 in adult subject with naturally acquired influenza.
  • T705aUS317: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects with Uncomplicated Influenza.
  • FEB-XR_301: A Phase 3, randomized, double blind, multicenter, placebo controlled study to evaluate the efficacy and safety of Febuxostat 40mg XR, 80mg XR, 40mg IR and 80mg IR in subjects with Gout.
  • FEB-XR_201: A Phase 2, randomized, double blind, multicenter, placebo controlled study to evaluate the efficacy and safety of Febuxostat 40mg XR, 80mg XR, 40mg IR and 80mg IR in subjects with Gout and Moderate Renal Impairment.
  • SP304203-03: A Multicenter, International, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation (CIC).
  • PAREXEL 216891Roxane Laboratories, Inc., FLSA-P100/50-PVCL: A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 ug and Salmeterol Xinafoate 50 ug Inhalation Powder Compared with Advair Diskus 100/50 in Subjects with Asthma.
  • I5Q-MC-CGAF: A Phase 2, Randomized, Double-Blind , Placebo and Active- Controlled Trial of LY2951742 In Patients with Mild to Moderate Osteoarthritis Pain of the Knee.
  • VX14-787-103: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX-787 Administered as Montherapy and One Dose Level of VX787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects
  • Protocol 42160443PAI3001: Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee.
  • C38072-AS-30025: Phase 3: A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils.
  • C38072-AS-30027 : A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 Weeks) in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils.
  • Protocol SP304203-01 : An Open-Label , Long-Term Safety and Tolerability Study of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC).
  • Protocol SP304203-05: Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C).
  • Protocol SP304203-06: An Open-Label, Long-Term Safety and Tolerability Study of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C).
  • C38072-AS-30025: A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils.
  • SAN2-15-151; Toujeo LPS14347: A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus.
  • C38072-AS-30066: An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older with Severe Eosinophilic Asthma.
  • EFC14833: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to evaluate the efficacy and safety of Sotagliflozin as Monotherapy in patients with Type 2 Diabetes Mellitus who have inadequate Glycemic control.